Human BNP and NT-proBNP: biomarkers for diagnosis of heart failure, predictive mortality and cardiovascular risk stratification.

14 Sep, 2016


no comments

Advanced ImmunoChemical offers antigens and corresponding high affinity monoclonal antibodies specific to recombinant human BNP, proBNP, and NT-proBNP for the development of sensitive, reliable immunoassays specific to regions not affected by glycosylation during proBNP processing.

Also a New Novel Single Epitope Sandwich (SES) assay for precise quantification of circulating BNP and proBNP in HF patients.


Click here to view Human BNP and NT-proBNP Product Performance Information

Human BNP and NT-proBNP and Related Products


Cat #8-NTpB-rh     Human recombinant NT-proBNP

Cat #8-pB-rh          Human recombinant proBNP

Cat #8-GproNP      Human recombinant proBNP, glycosylated 


Cat #2-BNP                Monoclonal mouse anti-human BNP

Cat #2-ICBNP            Monoclonal mouse anti-immune complex (24C5-


Cat #2-NT-proBNP     Monoclonal mouse anti-human NT-proBNP

BNP, or B-type natriuretic peptide, is a peptide hormone whose increased levels are often associated with critically ill heart failure patients (1). This family of natriuretic peptides, which also includes N-terminal proBNP, is responsible for maintaining homeostasis in the heart, producing urine, and widening blood vessels, among other functions, has shown to be useful in diagnosis of heart failure and the severity of cardiovascular diseases (2). Increased levels of BNP in the blood can allow physicians to determine whether or not a heart patient needs more critical care, assisting early diagnosis of serious cases of myocardial infarction as well (1, 2).

NT-proBNP testing is useful in the clinical setting because it assists early detection of the potential for in-hospital mortality in patients with heart failure (3). BNP and NT-proBNP is helpful in determining and perfecting therapies for cardiac diseases, monitoring the course of the disease, and assessing more accurate risk factors in individual patients (1, 2).


(1) Cowie, M.R., Mendez, G.F. (2002). BNP and congestive heart failure. Prog Cardiovasc Dis 44(4): 293-321.

(2) Mair, J. et al. (2001). The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 39(7): 571-88.

(3) Huang, Y.T. et al. (2016). N-terminal pro b-type natriuretic peptide (NT-pro-BNP) -based score can predict in-hospital mortality in patients with heart failure. Sci Rep 6: 29590.

Skip to toolbar